No Data
Kadimastem Calls for a Special General Meeting of Shareholders to Approve the Merger With NLS
NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce the Initial Closing of $500,000 of the Previously Announced $1 Million Fundraising by NLS Following Its Extraordinary General Meeting at a Share Price of $3.10
NLS Pharmaceutics Shareholders Approve Meeting Agenda
What's Going On With NLS Pharmaceuticals Stock Monday?
NLS Pharmaceutics Shares Rise More Than 50% on Merger Progress
Kadimastem Intends to Become a Publicly Traded Co on Nasdaq Through Merger
